Trump's Drug Pricing Deals Reshape Big Pharma
📊 PFE — Piyasa Yorumu
▲ up · 60%The news headline indicates that the Trump administration's drug pricing agreements are reshaping major pharmaceutical companies. This can be interpreted as a positive regulatory environment signal for large drug firms such as Pfizer. Technical indicators also support this optimistic outlook: the RSI is above the neutral zone at 60, the MACD is above its signal line, and the price is trading above both the 20-day and 50-day moving averages. An upward movement can be expected in the short term, but one should not be overly aggressive.
📊 ABBV — Piyasa Yorumu
■ neutral · 60%Although the news headline suggests that drug pricing agreements could transform the sector, AbbVie (ABBV) shares have fallen 2.4% in the last 24 hours, with the RSI at 46, indicating neutral territory. The MACD remains negative but is approaching the signal line, which may signal weakening momentum. In the short term, the price is trading near the 20-day moving average (247.74), which should be monitored as a support level. The impact of the news may not yet be fully priced in, but no clear directional signal has emerged.
📊 BMY — Piyasa Yorumu
■ neutral · 60%The headline indicates that Trump's drug pricing agreements are transforming major pharmaceutical companies. This could be a potentially positive development for large drug firms such as BMY, though details remain unclear. Technical indicators show the RSI at 73.47, signaling overbought conditions, with the price trading above short-term averages. This suggests limited upside potential in the near term. Therefore, despite the positive news impact, I recommend a neutral outlook due to the overbought technical signals.